Home › Research › TREM2 and immune genetics
Shifting paradigms: The central role of microglia in Alzheimer's disease
Schwabe T, Srinivasan K, Rhinn H.. Neurobiology of disease, 2020-06-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Recent human genetic studies have challenged long standing hypotheses about the chain of events in Alzheimer's disease (AD), as the identification of genetic risk factors in microglial genes supports a causative role for microglia in the disease. Parallel transcriptome and histology studies at the single-cell level revealed a rich palette of microglial states affected by disease status and genetic risk factors. Taken together, those findings support microglia dysfunction as a central mechanism in AD etiology and thus the therapeutic potential of modulating microglial activity for AD treatment.
What this study adds
Evidence grade: Low
This is a narrative review. This review argues that genetic and single-cell studies point to microglia dysfunction as a central mechanism in Alzheimer's disease, supporting the idea of modulating microglial activity as a treatment approach. It is a review of existing evidence and does not itself test any treatment in patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schwabe, T., Srinivasan, K., & Rhinn, H. (2020). Shifting paradigms: The central role of microglia in Alzheimer's disease. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2020.104962
Vancouver
Schwabe T, Srinivasan K, Rhinn H. Shifting paradigms: The central role of microglia in Alzheimer's disease. Neurobiology of disease. 2020. doi:10.1016/j.nbd.2020.104962. PMID: 32535152.
BibTeX
@article{schwabe2020-32535152,
author = {Schwabe, T. and Srinivasan, K. and Rhinn, H.},
title = {{Shifting paradigms: The central role of microglia in Alzheimer's disease}},
journal = {Neurobiology of disease},
year = {2020},
doi = {10.1016/j.nbd.2020.104962},
pmid = {32535152},
url = {https://doi.org/10.1016/j.nbd.2020.104962}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Parallel transcriptome and histology studies at the single-cell level revealed a rich palette of microglial states affected by disease status and genetic risk factors.
- Taken together, those findings support microglia dysfunction as a central mechanism in AD etiology and thus the therapeutic potential of modulating microglial activity for AD treatment.
- Here we review how human genetic studies discovered microglial AD risk genes, such as TREM2, CD33, MS4A and APOE, and how experimental studies are beginning to decipher the cellular functions of some of these genes.
- Our review also focuses on recent transcriptomic studies of human microglia from postmortem tissue to critically assess areas of similarity and dissimilarity between human and mouse models currently in use in order to better understand the biology of innate immunity in AD.
Why it matters
This review argues that genetic and single-cell studies point to microglia dysfunction as a central mechanism in Alzheimer's disease, supporting the idea of modulating microglial activity as a treatment approach. It is a review of existing evidence and does not itself test any treatment in patients.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of disease) |
| Journal's citation record | 2 / 4 | Neurobiology of Disease: journal h-index 225 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 85 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.6 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 4.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hervé Rhinn: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Alector (United States): institution h-index 60 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32535152) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.nbd.2020.104962
- PubMed: 32535152
- Original source →
- Free full text: Neurobiology of Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 78.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also in TREM2 and immune genetics
84 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.